PANOVA-4: Pilot, Single arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Gemcitabine; Paclitaxel
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Therapeutic Use
Acronyms PANOVA-4
Sponsors Bio-America

Most Recent Events

19 Feb 2025 Planned End Date changed from 31 Dec 2025 to 27 Nov 2025.
19 Feb 2025 Planned primary completion date changed from 31 Dec 2025 to 27 Nov 2025.
13 Jan 2025 According to a Novocure Limited media release, data from this stud anticipated in 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight